<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119343">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01912170</url>
  </required_header>
  <id_info>
    <org_study_id>DUOLI_GD</org_study_id>
    <nct_id>NCT01912170</nct_id>
  </id_info>
  <brief_title>Effect of Omega-3 Fatty Acids on Insulin Sensitivity in Chinese Gestational Diabetic Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <authority>Ethics Committee of the College of Biosystem Engineering &amp; Food Science, Zhejiang University: China</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to examine the change of fasting insulin, glucose, insulin sensitivity and
      related traits in response to the 14 wk treatment of omega-3 fatty acids, including fish oil
      (n=25) and flaxseed oil(n=25), in Chinese gestational diabetic patients. Corn oil(n=25),
      rich in omega-6 fatty acids, will be selected as a controlled oil. The intervention will
      start from the third trimester of these pregnant women and finish at the 4wk after the birth
      of their children. The investigators hypothesize that omega-3 fatty acids could improve
      insulin sensitivity and glucose metabolism in these patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>fasting glucose</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting insulin</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>birth weight, length of children</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>blood lipids, inflammatory markers</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>fish oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive fish oil capsules, at a dose of 2g/day. Each 1g capsule will contain 220mg of EPA and 170mg of DHA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flaxseed Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive flaxseed oil capsule, at a dose of 2g/day. Each 1g capsule will contain 550mg of ALA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Supplementation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil</intervention_name>
    <arm_group_label>fish oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flaxseed oil</intervention_name>
    <arm_group_label>Flaxseed Oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1)gestational diabetes 2) female, &lt;40 years old 3)willing to participant in the trial

        Exclusion Criteria:

          -  1）type 1 diabetes or type 2 diabetes before pregnancy 2）Deny to sign the informed
             consent 3）Family history of hypertriglyceridemia or fasting triglyceride&gt;4.56 mmol/L
             4）Have severe liver disease, kidney disease or cancer 5)Participating in the other
             clinical trial within 30 days 6)Other diseases or conditions, for which the doctor of
             the patients do not    agree his or her participating
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jiaxing Women's and Children's Hospital</name>
      <address>
        <city>Jiaxing</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huijuan Liu</last_name>
    </contact>
    <investigator>
      <last_name>Duo Li, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 27, 2013</lastchanged_date>
  <firstreceived_date>July 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Duo li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>omega-3 fatty acid</keyword>
  <keyword>gestational diabetes</keyword>
  <keyword>insulin sensitivity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
